Loren Data's SAM Daily™

FBO DAILY ISSUE OF MARCH 26, 2005 FBO #1216
MODIFICATION

B -- Breeding, Care and Support of Transgenic Mouse Colony of Mammary Cancer

Notice Date

3/24/2005
 

Notice Type

Modification
 

NAICS

541710 — Research and Development in the Physical, Engineering, and Life Sciences
 

Contracting Office

Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
 

ZIP Code

20852
 

Solicitation Number

N02-RC-57003-74
 

Response Due

4/4/2005
 

Archive Date

4/19/2005
 

Point of Contact

Odessa Henderson, Contract Specialist, Phone (301) 435-3812, Fax (301) 402-6699,
 

E-Mail Address

oh4o@nih.gov
 

Small Business Set-Aside

Total Small Business
 

Description

Amendment 1 As a result of the combined synopsis solicitation below the following questions were received in the contracts office. The due date for responses is unchanged. The questions and answers are as follows: Question 1: Will "replacement" FVB/N wild type (+/+)females be provided as needed by the Government, or will a colony breeding replacements need to be maintained? Answer 1: The Government shall replace wild-type females to contractor as needed or requested. It is important to point out that these are commercially available wild-type C57BL/6 (B6) mice, not FVB/N mice. Question 2: It is not clear whether the Government wants only hemizygous (T/+) females retained/produced for research use, or if they want hemizygotes of both sexes. Answer 2: The Government wants only hemizygous females retained/produced for research use. Hemizygous males will only be maintained and used for breeding. Question 3: The Government refers to producing non-transgenic mice. Does it mean FVB/N wild type (+/+) animals, or animals produced by breeding found to be non-transgenic during PCR analysis? Answer 3: Non-transgenic mice refer to female progeny that do not express the transgene by PCR analysis. Question 4: Does the Government intend to set a specific production quota by gender? Answer 4: For male transgenic mice, this will be based on establishing breeding pairs and setting aside a small reserve for replacement. For female mice (transgenic and non-transgenic), this will be based on numbers specified in the contract. Question 5: The RFP states that one to one breeding is how the breeders should be paired but does not clarify what sex and ages of progeny are needed. NOTE: THIS NOTICE WAS NOT POSTED TO WWW.FEDBIZOPPS.GOV ON THE DATE INDICATED IN THE NOTICE ITSELF (24-MAR-2005); HOWEVER, IT DID APPEAR IN THE FEDBIZOPPS FTP FEED ON THIS DATE. PLEASE CONTACT fbo.support@gsa.gov REGARDING THIS ISSUE.
 

Web Link

Link to FedBizOpps document.
(http://www.eps.gov/spg/HHS/NIH/RCB/N02-RC-57003-74/listing.html)
 

Place of Performance

Address: National Cancer Institute Bethesda, Maryland

Zip Code: 20892

Country: USA
 

Record

SN00776081-F 20050326/050324215309 (fbodaily.com)
 

Source

FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |